As we prepare our lead therapeutic, BNZ132-1-40, for human trials...We will benefit tremendously from [Eric's] industry-leading insights, as well as his acumen for developing business strategy.
Irvine, CA (PRWEB) April 12, 2016
Bioniz Therapeutics, a biopharmaceutical company leading the discovery and development of first-in-class multiple-cytokine inhibitory therapeutics to address immuno-inflammatory diseases and cancer immunotherapy, announced today that Eric Carter, most recently the Chief Medical Officer of Allergan, Inc (AGN), has joined the company as Chairman of the Scientific and Clinical Advisory Board.
“Eric is a perfect addition at a perfect time,” said Dr. Nazli Azimi, Bioniz’s CEO. “As we prepare our lead therapeutic, BNZ132-1-40, for human trials, it is essential to continue recruiting top tier professionals to ensure our success. Eric’s more than two decades of experience as a clinical leader has spanned a multitude of company sizes and therapeutic classes. We will benefit tremendously from his industry-leading insights, as well as his acumen for developing business strategy, which will be vital given the broad potential and novelty of our platform.”
Of his new position with Bioniz, Dr. Carter stated that, “Bioniz Therapeutics is an emerging biotechnology company built on a foundation of outstanding and innovative science that has created a first-in-class platform technology aimed at treating serious immunologically-mediated diseases. It is led by a growing group of professionals who blend talent, passion and dedication to the pursuit of the company goals. Both Bioniz’s Scientific Advisory Board and collaborators, as well as their highly-regarded Board of Directors, provide the world-renowned expertise and experience needed to guide Bioniz to success.”
Dr. Carter added “It is this potent combination of science and people that has attracted me to Bioniz, where in my role as Chairman of the Scientific and Clinical Advisory Board, I intend to help pursue the goal of bringing to patients with serious unmet medical needs, differentiated medical treatments of value”
Beyond driving clinical implementation and research strategy, Dr. Carter will also assume duties guiding the discussion of the scientific advisory meetings of Bioniz Therapeutics, which includes industry giants such as Dr. Thomas Waldmann, member of the National Academy of Sciences, an early pioneer of immunotherapy, and Chief of the Lymphoid Malignancies Branch of NCI at NIH; Dr. Robert Gallo, member of the National Academy of Sciences, twice recipient of Lasker Award, discoverer of the HTLV-1 virus and co-discoverer of HIV, and Director of the Institute of Human Virology (IHV) at the University of Maryland School of Medicine; Dr. Bana Jabri, Director of Research at the University of Chicago’s Celiac Disease Center; Dr. Steven Jacobson, Chief of the Viral Immunology Section of the Division of Neuroimmunology & Neurovirology, NINDS at the NIH, and Dr. Yutaka Tagaya, Bioniz’s Co-Founder and a leading immunologist with the IHV/University of Maryland School of Medicine.
Bioniz is a biopharmaceutical company leading the discovery and development of first-in-class multiple-cytokine inhibitory therapeutics to address immuno-inflammatory diseases and cancer, with an initial focus on orphan diseases. Bioniz leverages a world class expertise in cytokine biology and a first-in-class therapeutic platform, originating in research conducted at the National Institutes of Health, to create a new generation of multiple-cytokine inhibitors with selective specificity. Selective targeting of multiple cytokines that have redundant functions improves on the traditional approach of single anti-cytokine therapy. Bioniz’s technology is protected by US and international patents, which are solely owned by Bioniz. For more information, please visit http://www.bioniz.com.